In vitro effects of poly-N-acetyl glucosamine on the activation of platelets in platelet-rich plasma with and without red blood cells.
BACKGROUND
This study was performed to assess the effect of poly-N-acetyl glucosamine fiber slurry on plasma clotting proteins, platelets, and red blood cells in the clotting of the blood.


METHODS
Citrate phosphate dextrose whole blood was stored at 22degreesC for 48 hours to prepare platelet-poor plasma, platelet-rich plasma (PRP), and PRP plus red blood cells with hematocrit values of 20%, 35%, and 45% with and without an equal volume of poly-N-acetyl glucosamine fibers (1 mg/mL 0.9% NaCl).


RESULTS
Thromboelastogram data show that poly-N-acetyl glucosamine fibers (p-GlcNAc) significantly reduced the R time in platelet-poor plasma, PRP, and PRP supplemented with red blood cells. Poly-N-acetyl glucosamine fibers increased, but not significantly, Annexin V and factor X binding to platelets, platelet microparticles, and red blood cell Annexin V binding. Poly-N-acetyl glucosamine fibers increased the production of thromboxane B2 by PRP.


CONCLUSIONS
Poly-N-acetyl glucosamine slurry activates platelets.
Valeri
C Robert
CR
Naval Blood Research Laboratory, Boston University School of Medicine, Boston, Massachusetts 02118, USA.
Srey
Rithy
R
Tilahun
Daniel
D
Ragno
Gina
G
D000117:Acetylglucosamine / Q000737:chemistry / Q000494:pharmacology*; D017304:Annexin A5 / Q000032:analysis / Q000097:blood / Q000187:drug effects; D001779:Blood Coagulation Factors / Q000187:drug effects; D001792:Blood Platelets / Q000737:chemistry / Q000187:drug effects*; D004353:Drug Evaluation, Preclinical; D004912:Erythrocytes / Q000737:chemistry / Q000187:drug effects*; D005170:Factor X / Q000032:analysis / Q000187:drug effects / Q000378:metabolism; D005338:Fibrin Fibrinogen Degradation Products / Q000187:drug effects / Q000378:metabolism; D005340:Fibrinogen / Q000032:analysis / Q000187:drug effects / Q000378:metabolism; D006400:Hematocrit; D006490:Hemostatics / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D019007:P-Selectin / Q000032:analysis / Q000097:blood / Q000187:drug effects; D010446:Peptide Fragments / Q000097:blood / Q000187:drug effects; D015539:Platelet Activation / Q000187:drug effects*; D010979:Platelet Function Tests; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000032:analysis / Q000187:drug effects / Q000378:metabolism; D019038:Platelet Glycoprotein GPIb-IX Complex / Q000032:analysis / Q000187:drug effects / Q000378:metabolism; D011516:Prothrombin / Q000187:drug effects; D013916:Thrombelastography; D013929:Thromboxane B2 / Q000097:blood; D013997:Time Factors
D017304:Annexin A5; D001779:Blood Coagulation Factors; D005338:Fibrin Fibrinogen Degradation Products; D006490:Hemostatics; D019007:P-Selectin; D010446:Peptide Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D019038:Platelet Glycoprotein GPIb-IX Complex; C036309:fibrin fragment D; C113831:poly-N-acetyl glucosamine; C045879:prothrombin fragment 1.2; D013929:Thromboxane B2; D011516:Prothrombin; D005170:Factor X; D005340:Fibrinogen; D000117:Acetylglucosamine